PRLD · Prelude Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $12.14M | $7.00M | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $94.30M | $118.00M | $103.39M | $92.89M | $86.78M | $48.18M |
| SG&A | $22.41M | $28.72M | $28.88M | $30.65M | $26.96M | $10.59M |
| Total Operating Expenses | $116.71M | $146.71M | $132.28M | $123.54M | $113.73M | $58.76M |
| D&A | $1.71M | $1.77M | $1.17M | $1.32M | $915.0K | $542.0K |
| Operating Income | ($104.57M) | ($139.71M) | ($132.28M) | ($123.54M) | ($113.73M) | ($58.76M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($99.50M) | ($127.17M) | ($121.83M) | ($115.44M) | ($111.69M) | ($56.93M) |
| EPS - Basic | ($1.29) | ($1.68) | ($2.02) | ($2.43) | - | - |
| EPS - Diluted | ($1.29) | ($1.68) | ($2.02) | ($2.43) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M | $218.31M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.98M | $7.73M | $4.58M | $6.78M | $7.84M | $3.92M |
| Current Assets | $105.69M | $135.90M | $235.59M | $204.38M | $295.12M | $220.81M |
| Total Assets | $141.31M | $175.51M | $277.67M | $220.50M | $305.10M | $223.59M |
| Current Liabilities | $52.99M | $25.64M | $21.83M | $21.70M | $19.20M | $11.38M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.20M | $11.41M |
| Stockholders' Equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.90M | $212.18M |
| Retained Earnings | ($683.06M) | ($583.56M) | ($456.39M) | ($334.56M) | ($219.12M) | ($107.43M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($56.30M) | ($102.89M) | ($107.06M) | ($83.73M) | ($83.53M) | ($46.18M) |
| Investing Cash Flow | $53.46M | $90.19M | ($34.65M) | $81.69M | ($263.80M) | ($621.0K) |
| Financing Cash Flow | $24.82M | ($120.0K) | $136.40M | $815.0K | $164.90M | $246.23M |
| CapEx | $67.0K | $764.0K | $3.51M | $3.02M | $2.32M | $621.0K |
| Free Cash Flow | ($56.37M) | ($103.65M) | ($110.58M) | ($86.75M) | ($85.85M) | ($46.80M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -861.3% | -1995.9% | - | - | - | - |
| EBITDA margin | -847.2% | -1970.6% | - | - | - | - |
| Net margin | -819.6% | -1816.8% | - | - | - | - |
| Free cash flow margin | -464.3% | -1480.7% | - | - | - | - |
| FCF / Net income | 0.57 | 0.82 | 0.91 | 0.75 | 0.77 | 0.82 |
| R&D / Revenue | 776.8% | 1685.6% | - | - | - | - |
| SG&A / Revenue | 184.6% | 410.3% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -70.4% | -72.5% | -43.9% | -52.4% | -36.6% | -25.5% |
| Return on equity | -145.0% | -96.7% | -51.4% | -59.1% | -39.1% | -26.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 |
| Quick ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 |
| Cash ratio | 0.67 | 0.49 | 1.16 | 1.41 | 1.66 | 19.19 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 2.06 | 1.34 | 1.17 | 1.13 | 1.07 | 1.05 |
| Liabilities / Assets | 0.51 | 0.25 | 0.15 | 0.11 | 0.06 | 0.05 |
| Efficiency | ||||||
| Asset turnover | 0.09 | 0.04 | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.3x | 0.7x | 1.1x | 1.4x | - | - |
| P / S | 18.4x | 13.8x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 73.4% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 25.2% | -5.6% | -7.1% | -8.6% | -93.5% | - |
| Net income growth (YoY) | 21.8% | -4.4% | -5.5% | -3.4% | -96.2% | - |
| EPS growth (YoY) | 23.2% | 16.8% | 16.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 45.6% | 6.3% | -27.5% | -1.0% | -83.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -47.8% | -44.6% | 21.3% | -31.6% | 34.7% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-5.64
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Prelude Therapeutics Inc against the 5 most active filers in the same SIC group.